Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2024 | $24.00 | Buy | Goldman |
| 1/30/2024 | $20.00 | Buy | Citigroup |
| 7/21/2023 | $21.00 | Outperform | Oppenheimer |
| 5/5/2023 | $16.00 | Overweight | CapitalOne |
| 2/22/2023 | $12.00 | Outperform | Credit Suisse |
| 7/6/2022 | $16.00 | Buy | Canaccord Genuity |
| 6/9/2022 | $12.00 | Neutral → Buy | H.C. Wainwright |
| 2/28/2022 | Neutral | HC Wainwright & Co. |
Goldman initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $24.00
Citigroup initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Oppenheimer initiated coverage of Olema Pharmaceuticals with a rating of Outperform and set a new price target of $21.00
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarterNew clinical data for palazestrant (OP-1250) in combination with CDK4/6 inhibitors to be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) in December Strong cash, cash equivalents and marketable securities position of $276.9 million as of September 30, 2023 SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancer
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced the appointment of Scott Garland to the company's Board of Directors. Mr. Garland brings more than 30 years of biopharmaceutical industry experience with deep commercial and executive leadership expertise. "We are delighted to have Scott join our Board of Directors at such an exciting time for Olema," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "His broad experien
• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela Klein, M.D., will become a senior advisor and member of Olema's Scientific Advisory Board SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced the appointment of Naseem Zojwalla, M.D., as Chief Medical Officer. Bringing more than 15 years of oncology and clinical deve
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) New clinical data for palazestrant (OP-1250) in combination with ribociclib to be presented at the San Antonio Breast Cancer Symposium (SABCS) in DecemberIND submission for OP-3136 expected before year end; clinical study to initiate early 2025Cash, cash equivalents, and marketable securities of $214.8 million as of September 30, 2024 SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NAS
SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that its management team will participate in the following upcoming investor conferences: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET)Location: London, UKFormat: Fireside Chat 7th Annual Evercore HealthCONx ConferenceDate: Tuesday, December 3, 2024, at 2:10 p.m. ETLocation: Loews Coral Gables Hotel in Coral Gables, FLFormat: Fireside Chat C
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to one new employee to purchase an aggregate of 2,500 shares of the Company's common stock, effective as of November 1, 2024. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of November 1, 2024, as an inducement material to the new employees entering int
Gainers Concord Medical Services (NYSE:CCM) shares moved upwards by 51.9% to $1.2 during Tuesday's regular session. The market value of their outstanding shares is at $52.1 million. Annexon (NASDAQ:ANNX) shares increased by 32.96% to $6.09. The company's market cap stands at $562.7 million. Olema Pharmaceuticals (NASDAQ:OLMA) stock moved upwards by 26.7% to $14.9. The company's market cap stands at $833.4 million. Pasithea Therapeutics (NASDAQ:KTTA) shares moved upwards by 22.59% to $7.0. The market value of their outstanding shares is at $7.3 million. Fresh2 Group (NASDAQ:FRES) stock moved upwards by 21.12% to $0.43. The company's market cap stands at $10.5 million. I-MAB (NASDAQ:IMAB
HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 price target.
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results. SAIC reported a 9% revenue decline year over year in the fiscal first quarter of 2025 to $1.847 billion, marginally beating the analyst consensus estimate of $1.844 billion. Adjusted EPS of $1.92 was in line with the analyst consensus estimate, according to data from Benzinga Pro. SAIC shares dipped 11% to $119.91 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Microbot Medical Inc. (NASDAQ:MBOT) jumped 92.5% to $1.9301 after the company received FDA approval to proceed with its pivotal human clinical trial. Bio-Pa
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted the
Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to be presented at the ESMO Breast Cancer Annual Congress 2024 in Berlin, Germany. Olema will host an investor conference call on May 15, 2024, at 8:00 a.m. ET to review the dataInvestigational New Drug (IND) application for OP-3136, a novel KAT6 inhibitor, expected to be filed with FDA in late 2024Cash, cash equivalents and marketable securities of $249.0 million as of March 31, 2024 SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that it will present new clinical data from the Company's ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress 2024 taking place May 15-17, 2023, in Berlin, Germany. Details of the ESMO Breast Cancer Annual Congress 2024 poster presentation are: Title: